📊 SLNCF Key Takeaways
Is Silence Therapeutics plc (SLNCF) a Good Investment?
Company experiencing catastrophic business deterioration with 98.7% revenue collapse and -62.3M annual operating cash burn against only 11.3M cash reserves (~2 months runway). Massive operating losses of -91.1M indicate fundamental product/business failure with no visible path to profitability.
Silence Therapeutics plc Key Strengths (SLNCF)
- Zero debt burden provides financial flexibility
- Positive gross margin of 61.5% on remaining product sales
- Stockholders equity of 62.3M provides book value cushion
SLNCF Stock Risks: Silence Therapeutics plc Investment Risks
- Critical cash runway of ~2 months at current -62.3M annual burn rate
- 98.7% YoY revenue collapse suggests loss of primary product or failed pipeline
- Operating losses of -91.1M unsustainable relative to 559K revenue base
- No evidence of near-term catalysts for revenue recovery or profitability
Key Metrics to Watch
- Quarterly operating cash burn rate and cash balance depletion
- Revenue stabilization or pipeline announcements indicating business recovery
- Cost restructuring progress and timeline to cash flow breakeven
Silence Therapeutics plc (SLNCF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.72x current ratio provides a solid financial cushion.
SLNCF Profit Margin, ROE & Profitability Analysis
SLNCF vs Healthcare Sector: How Silence Therapeutics plc Compares
How Silence Therapeutics plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Silence Therapeutics plc Stock Overvalued? SLNCF Valuation Analysis 2026
Based on fundamental analysis, Silence Therapeutics plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Silence Therapeutics plc Balance Sheet: SLNCF Debt, Cash & Liquidity
SLNCF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Silence Therapeutics plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.33 indicates the company is currently unprofitable.
SLNCF Revenue Growth, EPS Growth & YoY Performance
SLNCF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $142.0K | -$15.0M | $-0.11 |
| Q3 2025 | $159.0K | -$2.3M | $-0.15 |
| Q2 2025 | $224.0K | -$2.3M | $-0.14 |
| Q1 2025 | $142.0K | -$2.3M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Silence Therapeutics plc Dividends, Buybacks & Capital Allocation
SLNCF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Silence Therapeutics plc (CIK: 0001479615)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SLNCF
What is the AI rating for SLNCF?
Silence Therapeutics plc (SLNCF) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SLNCF's key strengths?
Claude: Zero debt burden provides financial flexibility. Positive gross margin of 61.5% on remaining product sales.
What are the risks of investing in SLNCF?
Claude: Critical cash runway of ~2 months at current -62.3M annual burn rate. 98.7% YoY revenue collapse suggests loss of primary product or failed pipeline.
What is SLNCF's revenue and growth?
Silence Therapeutics plc reported revenue of $559.0K.
Does SLNCF pay dividends?
Silence Therapeutics plc does not currently pay dividends.
Where can I find SLNCF SEC filings?
Official SEC filings for Silence Therapeutics plc (CIK: 0001479615) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SLNCF's EPS?
Silence Therapeutics plc has a diluted EPS of $-0.63.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SLNCF's fundamental grade?
Based on our AI fundamental analysis in June 2026, Silence Therapeutics plc has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SLNCF stock overvalued or undervalued?
Valuation metrics for SLNCF: ROE of -142.2% (sector avg: 15%), net margin of -15,851.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SLNCF's AI grade for 2026?
Our dual AI analysis gives Silence Therapeutics plc a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SLNCF's free cash flow?
Silence Therapeutics plc's operating cash flow is $-62.3M, with capital expenditures of $55.0K. FCF margin is -11,149.6%.
How does SLNCF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -15,851.9% (avg: 12%), ROE -142.2% (avg: 15%), current ratio 8.72 (avg: 2).